Gastric Adenocarcinoma study: PULSAR
Official title PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer
ClinicalTrials.gov ID: NCT07607119
What this study is testing
- What it's testing
- The purpose of this single-center, phase II study is to look at the clinical how well it works and how safe it is of combining first-line systemic therapy plus immunotherapy with personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR) in patients with unresectable locally advanced gastric cancer.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 and older
You may be able to join if
- Age 19 or more years. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. Histologically confirmed gastric adenocarcinoma.
- Unresectable, locally advanced extent at initial staging (Para-aortic lymph node [PALN] and Supraclavicular lymph node [SCN] metastases are allowed).
- Has completed 3 or more cycles of first-line systemic therapy combined with immunotherapy without evidence of disease progression.
- Presence of at least one evaluable lesion according to RECIST v1.1 that is deemed safely irradiable by the investigator.
- Voluntary written informed consent provided by the subject.
You likely can't join if
- Pregnant or lactating women. Presence of brain metastases or leptomeningeal involvement.
- Inability or unwillingness to comply with the study protocol procedures.
The study team makes the final eligibility decision.
Where it is enrolling
- Seoul, Select Province/State, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Seoul, Select Province/State, South Korea. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.